S. Edwin Fineberg, MD
Dept. of Medicine
Division of Endocrinology, Diabetes & Metabolism
Dartmouth College, Hanover, NH
University of Vermont College of Medicine, Burlington, VT
Hospital of the University of Pennsylvania, Philadelephia, PA
Rotating Internship, 1962-3
Philadelphia General Hospital, Philadelphia, PA
Resident, Internal Medicine, 1965-7
Johns Hopkins University School of Medicine, Baltimore, MD
Fellow and Research Trainee, Endocrinology, 1967-8
Boston University School of Medicine, Boston, MA
Research Fellow, Medicine, 1968-70
My Clinical research activities have spanned the entire length of my career as an academic trainee in endocrinology and metabolism and as an academic endocrinologist. These activities include:
Federally funded research with regard to human proinsulin, growth hormone and glucagon.
In addition, the effects of nutrition on glucose metabolism, and most recently in an ADA project, the effects of animal and vegetable based diets. I have been a collaborative investigator in the DPP 2 trial. I have also run a core laboratory for the PEPI trial and a coauthor on a number of PEPI related publications.
Industry sponsored research has included a long term collaborative relationship with Lilly laboratories over a span of 20 years. I had a primary responsibility for inclusion in insulin trials of immunological studies and my laboratory designed methodology and carried out measures of insulin antibodies in all insulin trials worldwide through the completion of the Lispro trials.
I have carried out drug trials on glipizide, troglitazone, recombinant human ngf, Acarbose, and pioglitazone as a PI. I aso have participated in trials of HMG co A reductase inhibitors and aldose reductase inhibitors.
I have designed and carried out trials of glucose monitoring instruments and a HbA1c devices from Bayer, devices from Medisense and GDS. I currently am participating in 2 drug trials one of which I helped design as a consultant.
I currently consult with or serve on advisory panels for Lilly, Pfizer, Aventis and Amylin with regard to their drug development programs.
DRC Membership Category: